The FDA has accepted a Novartis’ biologics application for its sickle cell disease candidate crizanlizumab (SEG101). This puts the drug under priority review, which slashes four months off its evaluation time to just six months in total.
If approved, it could join multiple sclerosis drug Mayzent, spinal muscular atrophy gene therapy Zolgensma and age-related macular degeneration candidate brolucizumab—which are also under priority review—among the Swiss drugmaker's most important launches these days.
Novartis plans to launch over 10 potential blockbuster drugs or new indications by 2021.
Click here to view the entire article.